Curasight announed positive readout from a preclinical study in aggressive brain cancer (glioblastoma), showing that uTREAT inhibited tumour growth. This takes the company closer to reaching the full potential of the theranostic platform where uTRACE and uTREAT work in combination offering diagnostics and treatment. Even though the development is at an early stage, we view this as supportive for the continued development of the treatment.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.